Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res. 2016;9:2–10.
Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.
Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014;12:1339–1346.
Hiraki S, Rinella ES, Schnabel F, Oratz R, Ostrer H. Cancer risk assessment using genetic panel testing: considerations for clinical application. J Genet Couns. 2014;23:604–617.
Beery TA, Williams JK. Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders. Genet Test. 2007;11:111–123.
Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA. 2007;298:1682–1684.
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31:1803–1805.
Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008;10:19–32.
Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Med J Aust. 2003;178:77–81.
Kaphingst KA, McBride CM. Patient responses to genetic information: studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice. Semin Nephrol. 2010;30:203–214.
Hollands GJ, French DP, Griffin SJ. The impact of communicating genetic risks of disease on risk-reducing health behaviour. BMJ. 2016;352:1/2p.
McBride CM, Wade CH, Kaphingst KA. Consumers’ views of direct-to-consumer genetic information. Ann Rev Genomics Hum Genet. 2010;11:427–446.
Peterson E, Chou W-YS, Gaysynsky A, et al. Communication of cancer-related genetic and genomic information: a landscape analysis of reviews. Transl Behav Med. 2018;8:59–70.
Epstein RM, Street RL. Patient-centered communication in cancer care: promoting healing and reducing suffering. Bethesda, MD: National Cancer Institute; 2007. P.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
Fleiss J, Levin B, Paik M. Statistical methods for rates and proportions. 3rd ed. New York: John Wiley & Sons; 2003.
Aktan-Collan K, Kaariainen H, Jarvinen H, et al. Psychosocial consequences of predictive genetic testing for Lynch syndrome and associations to surveillance behaviour in a 7-year follow-up study. Fam Cancer. 2013;12:639–646.
Agurs-Collins T, Ferrer R, Ottenbacher A, Waters EA, O’Connell ME, Hamilton JG. Public awareness of direct-to-consumer genetic tests: findings from the 2013 U.S. Health Information National Trends Survey. J Cancer Educ. 2015;30:799–807.
Alderfer MA, Zelley K, Lindell RB, et al. Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. 2015;121:286–293.
Thomassen G, Sarangi S. Evidence-based familial risk explanations in cancer genetic counselling. Health Risk Soc. 2012;14:607–626.
Vindigni S, Kaz A. Universal screening of colorectal cancers for Lynch syndrome: challenges and opportunities. Dig Dis Sci. 2016;61:969–976.
Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw. 2010;8:597–601.
Provenzale D, Gupta S, Ahnen DJ, et al. Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:1010–1030.
Slater MD, Long M, Bettinghaus EP, Reineke JB. News coverage of cancer in the United States: a national sample of newspapers, television, and magazines. J Health Commun. 2008;13:523–527.
Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267–1270.
Society of Gynecologic Oncology. SGO clinical practice statement: next generation cancer gene panels versus gene by gene testing. 2014. https://www.sgo.org/clinical-practice/guidelines/next-generation-cancer-gene-panels-versus-gene-by-gene-testing/. Accessed 3 May 2018.
Easton DF, Pharoah PDP, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243–2257.
Wolfe Schneider K, Anguiano A, Axell L, et al. Collaboration of Colorado cancer genetic counselors to integrate next generation sequencing panels into clinical practice. J Genet Couns. 2014;23:640–646.
Khoury MJ, Bowen MS, Clyne M, et al. From public health genomics to precision public health: a 20-year journey. Genet Med. 2018;20:574–582.
Slavin TP, Niell-Swiller M, Solomon I, et al. Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. Front Oncol. 2015;5:208.
Mills R, Haga SB. Genomic counseling: next generation counseling. J Genet Couns. 2014;23:689–692.
US Food and Drug Administration. FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599560.htm. Accessed 7 May 2018.
Kaphingst KA, Goodman MS. Importance of race and ethnicity in individuals’ use of and responses to genomic information. Pers Med. 2016;13:1–4.
McBride CM, Bowen D, Brody LC, et al. Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med. 2010;38:561–566.